Xeris Biopharma (NASDAQ:XERS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Xeris Biopharma (NASDAQ:XERS) in a research note released on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

XERS has been the topic of several other research reports. Barclays began coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Piper Sandler increased their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Finally, Oppenheimer restated an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.08.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $6.02 on Monday. Xeris Biopharma has a fifty-two week low of $3.59 and a fifty-two week high of $10.08. The firm has a 50-day simple moving average of $7.20 and a two-hundred day simple moving average of $7.63. The company has a market cap of $998.84 million, a P/E ratio of -60.19 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Equities research analysts forecast that Xeris Biopharma will post -0.41 EPS for the current year.

Insider Buying and Selling

In related news, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the sale, the insider owned 1,685,426 shares of the company’s stock, valued at approximately $13,483,408. This represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the completion of the sale, the insider owned 2,705,346 shares of the company’s stock, valued at approximately $19,153,849.68. This represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 223,641 shares of company stock worth $1,628,285 in the last 90 days. 4.56% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the period. Geode Capital Management LLC increased its position in shares of Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp grew its stake in Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after purchasing an additional 378,595 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after purchasing an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 EPS beat — Xeris reported $0.06 GAAP EPS vs. the $0.03 consensus, signaling profit improvement and operational progress. Press Release
• Positive Sentiment: Raised FY2026 revenue guidance — Xeris gave revenue guidance of $375.0M–$390.0M, above the Street (~$370.3M), implying continued top-line growth for the year. Guidance detail is in the company release. Press Release
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a Buy and set a $10 price target (~66% upside vs. current levels), which can support investor confidence and buying interest. Analyst Note
• Neutral Sentiment: Conference call / transcripts available — Management commentary is posted (earnings call transcript and replay); investors should listen for product mix, Recorlev trends and margin drivers. Earnings Transcript
• Neutral Sentiment: Mixed revenue print — Reported revenue was $85.81M (vs. ~$86.0M consensus) — essentially flat to expectations; analysts will parse product-level trends and Recorlev dynamics for the FY outlook. See analyst breakdown. Zacks Analysis
• Negative Sentiment: Regulatory / exclusivity risk — Coverage discusses valuation risks as Xeris fights to protect Recorlev exclusivity; any adverse outcome could materially affect future sales and valuation. Risk Article
• Negative Sentiment: Stock reaction and technicals — Despite the EPS beat and raised revenue guidance, the stock declined on the session with elevated volume and remains below key moving averages, which can pressure short-term momentum. Press Release

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.